期刊名称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
DARU is a Persian name, meaning drug. DARU has been published in Persian from 1991 to 1995,in Persian with English abstract from 1995 to 1999 and only in English language form the early of 1999 four times a year. The main scope of this journal is to publish original research articles in pharmaceutical sciences. Editorial board of DARU are specialist in different areas of pharmacy. All submitted manuscripts are initially evaluated in the editorial meeting (regularly is held every two weeks) to determine peer reviewers in the related subjects. On the basis of reviewer’s comments, the editorial committee decide about the acceptance or rejection of the submitted manuscript and in the case that the manuscript is acceptable, the main author will be asked to revise it according to the reviewer’s comments or reply to their questions and comments. Final decision about acceptance of a manuscript for publication in DARU will be made in the editorial board meeting on the basis of reviewer’s comments, author’s responses or revisions. Outstanding basic and applied papers, reviews, short communication, and notes in the pharmaceutical and biomedical fields especially pharmaceutical and biomedical analyses, chemistry & medicinal chemistry, medical biotechnology, pharmaceutics, pharmacognosy & natural products, toxicology & pharmacology, clinical pharmacy & pharmacotherapy, quality control of foods and drugs, social aspects of pharmacy, and drug design are welcome. It is believed that there are only a few international journals that have the same general scope as DARU has. Scientists and academicians in the field of drug-related matters could be audience of this journal. DARU is indexed and abstracted in the world-known bibliographical databases including Chemical Abstracts Service (CAS), International Pharmaceutical Abstracts (IPA), Excerpta Medica/EMBASE, Biological Abstracts (BIOSIS), Index Medicus for WHO Eastern Mediterranean Region (IMEMR), Natural Product Extracts (NAPRALERT), CAB Abstracts, Index Copernicus, Global Health, SCOPUS, Thomson ISI Master Journal List and EBSCO.
Instructions to Authors
1-Aims and Scope
DARU is an open-access journal for publication of results of outstanding basic and applied research of high scientific levels in the pharmaceutical and biomedical fields. Manuscripts in chemistry & medicinal chemistry, clinical pharmacy & pharmacotherapy, drug design, medical biotechnology, pharmaceutics, pharmaceutical and biomedical analyses, pharmacognosy & natural products, toxicology & pharmacology, quality control of foods and drugs and social aspects of pharmacy are welcome.
DARU is indexed and abstracted in several bibliographical databases including SCI/Thompson Reuters ISI, SCOPUS, CAS, IPA, EMBASE, BIOSIS, IMEMR, NAPRALERT, CABI, Index Copernicus, Global Health, DOAJ, Free Medical Journals, and EBSCO Publication Co. DARU is also available online at TUMS website: http://journals.tums.ac.ir
2-Types of Manuscripts
DARU provides a medium for the publication of following articles:
• Original research articles
Novel findings that contribute to advancement of scientific knowledge in pharmaceutical and biomedical fields will be considered for publication in DARU as Original research article. These articles should be limited to a maximum of 6000 words or maximum 8 printed pages including a structured abstract of not more than 250 words and 8 figures and tables (combined).
• Short communications
New and important information resulting from limited studies but of the same level as original research article will be considered for publication as short communication. These manuscripts should have the same format requirement as full paper but should be limited to maximum 3000 words or maximum 4 printed pages including a structured abstract of not more than 150 words and 4 figures and tables (combined).
• Review articles
The results of various investigations in a given area of the pharmaceutical and biomedical sciences submitted by expertise in the field by invitation of the editorial board may be considered for publication as Review articles. These articles are not required to be divided into different sections but should have an abstract not more than 250 words and introduction sections. At list 10% of references of the review articles should be results of the author investigations published in internationally indexed journals.
• Letters to editor
Opinions on professional subjects and the comments to the articles recently published in DARU will be considered for publication as Letter to editor. Letters should not have subtitles and should be limited to 750 words or 1 printed page including maximum 4 references and 1 figure or table.
3-Editorial Policy
All manuscripts will be examined by the chief editor, an associate editor, a member of the editorial board and at least by two independent referees. Authors are requested to suggest names of potential reviewers. However selection of the reviewers is the authority of the chief editor and editorial board. DARU reserves the right to reject manuscripts that do not fulfill the criteria for submission of the manuscripts.
4-Submission of Manuscripts
Authors are requested to submit their manuscripts electronically, through http://journals.tums.ac.ir . Detailed step by step instruction can be found in the web site.
A cover letter written by the corresponding author stating that the manuscript has not been published elsewhere (except in the form of an abstract or as part of a published lecture or academic thesis) and is not concurrently under review for publication another journals should accompany the manuscript.
5-Preparation of the manuscripts
The manuscript should be typed by Microsoft Office Word program. The font of Times New Roman size 12 and double line spacing should be used. The abbreviations should be defined as first come; and data should be presented in SI units.
All plant and microorganism's scientific names should be written in italic.
Generic or chemical names of drugs should be used in the text except for studies on comparative effects of different brands.
The manuscript should be organized as title page, abstract, introduction, materials and methods, results, discussion or results and discussion, conclusion, references, Acknowledgments, tables, figures, and illustrations. Authors should state in the manuscript how they have adhered to ethical codes.
• Title page
This should include the title, the authors' names, affiliations, addresses, telephone and fax numbers and email address of the corresponding author, place where the work was undertaken and a short title for the running head. Title should be concise in providing information about the content. It should not be capitalized except for the first letter of the first word.
• Abstract
The abstract should contain a brief description of the following sections separately:
Background and the purpose of the study, methods, results and major conclusion.
• Key words
The abstract should be followed by a maximum of 6 keywords in order of importance pertinent to the subject.
• Introduction
This section should clearly define the purpose and importance of the research with special attention and suitably references to the background of the study.
• Materials and methods
This section should provide sufficient information about materials used, their specifications and sources of preparation. The name, model and place of manufacturing of instruments should be stated. Chemical terms should confirm to IUPAC rule. Experimental procedures should provide sufficient information to permit repetition of the work by other workers and /or gives references to the previously published methods.
DARU publishes the results of research involving human subjects only if such research has been conducted in full accordance with ethical principles and a statement describing approval by the Institutional Ethical Committee is required. Studies involving experimental animals must include a statement in the methods section indicating which guidelines were followed for the care and use of the animals
• Results
The important results should be stated with references to tables or figures or schemes. This section should be concise and must not repeat other parts of the manuscript.
• Discussion
This section should interpret the results in view of the problems outlined in the introduction and should not repeat the results. The potential of results with appropriate references should be clearly explained. Discussion can be combined with results in one section.
• Conclusion
A conclusion which elucidates the general implication of the results should be stated.
• Tables and Figures
These are essential to understand the text; the same data should not be presented in both tables and graphs. Abbreviations should be avoided or explained and all data should be identified. Tables or figures should be clearly drawn, headed with a short and descriptive caption and serially numbered in Arabic numerals and provided in separate sheets. A list of figures and tables should be submitted with the manuscript.
• References
Authors are responsible for the accuracy of all references. References should be numbered consecutively as they occur in the text in the parenthesis after last relevant word and listed in numerical order at the end of the text. For more information see the latest issue of the journal.
DARU adheres to the Vancouver style of reference lists (see Uniform Requirements for Manuscripts of the International Committee of Medical Journal Editors, http://www.icmje.org/index.html). Examples are as follow:
Zakeri-Milani P, Valizadeh H, Azarmi Y, Barzegar-Jalali M, Tajerzadeh H. Simultaneous determination of metoprolol, propranolol and phenol red in samples from rat in situ intestinal perfusion studies. DARU, 2006; 14:102-108
Fatolazadeh B, Hashemi FB, Emaneini M, Aligholi M, Nakhjavani F, Kazemi B. Detection of vancomycin resistant enterococci (VRE) isolated from urinary tract infections (UTI) in Tehran, Iran. DARU, 2006; 14: 141-145
Washington N, Wilson CG. Physiological factors affecting drug delivery and availability. In: Swarbrrick J, ed. Encyclopedia of pharmaceutical technology. NewYork, Marcel Decker. 1995; 465-478.
Lewis S.N,Miller G.A, Law A.B.. 3-Isothiazolones as Biocides US Patent 4105431 1978.Chem. Abstr 1979, 90, 54934.
• Acknowledgments
Acknowledgments should be described separately. Authors should disclose at the time of submission, information on financial conflicts of interest or other interests that may influence the manuscript. Authors may be asked to sign a "conflict of interest" form at the time of submission.
6-Proofs
Proofs will be sent to the corresponding author for checking. Authors are responsible for all statements in their works including changes made by editor after acceptance of the article.
7-Copyright Transfer
An agreement of copyright transfer to the publisher (Tehran Medical Sciences University) should be signed and passed as soon as the manuscript is accepted for publication.
There will be no page charge and one copy of the journal containing the published articles will be sent to individual authors.
Authors are encouraged to consider the latest issue of DARU for the general format of presentation.
More information about the journal and its previous issues are available at the following website: http://journals.tums.ac.ir/
Editorial Board
Abbas Shafiee, Chairman
Professor of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ali Khalaj, Chief Editor
Professor of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Alireza Vatanara, Assitinat Editor
Assistant Professor of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Abdollahi
Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Khosrow Adeli
Professor of Biochemistry, Department of Laboratory Medicine and Pathology, University of Toronto, Canada.
Gholamreza Amin
Professor of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mohsen Daneshtalab
Professor, Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy, Memorial University of Newfoundland, Canada.
Rasoul Dinarvand
Professor of Pharmaceutics, Dean of Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Hassan Ebrahimzadeh
Professor of Biology, Department of Biology, Faculty of Science, Tehran University, Tehran, Iran.
Hassan Farsam
Professor of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Padideh Ghaeli
Associate Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Fakhroldin Jamali
Professor of Pharmacokinetics, Faculty of Pharmacy, University of Alberta, Alberta, Canada
Mahmud Kajbaf
Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, Verona, Italy (Drug Metabolism, Lead Optimization Group).
Abbas Kebryaeezadeh
Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Shahram Khademi
Assistant Professor of Biochemistry, University of Iowa, Iowa City, Iowa, USA.
Soraya Madani
Director of Drug Regulatory Affairs, Novartis FDA Liaison and Policy Office, Rockville, MD, USA.
Firouz Matloubi Moghaddam
Professor of Chemistry, Department of Chemistry, Sharif University of Technology, Tehran, Iran.
Reza Mehvar
Professor of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Texas, USA.
Tim Meredith
Professor of Medicine and Pathology, Vanderbilt University Medical Center, Center for Clinical Toxicology, Nashville, TN, USA.
Mehran Moghadam
Associate Director, Celgene Corporation, San-Diego, CA, USA.
Mojtaba Mojtahedzadeh
Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ali Nokhodchi
Associated Professor of Pharmaceutics, Medway School of Pharmacy, University of Kent and Greenwich, Kent, UK.
Peter J. O'Brien
Professor of Pharmacology & Toxicology, Faculty of Pharmacy and Department of Pharmacology,
Faculty of Medicine, University of Toronto, Toronto, Canada.
Yadollah Omidi
Associate Professor, Department of Pharmaceutics, Faculty of Pharmacy. Tabriz University of Medical Sciences, Tabriz, Iran.
Keykavous Parang
Professor, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, RI, USA.
Morteza Rafiee-Tehrani
Professor of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Amin Rostami-Hodjegan
Professor of System Pharmacology and Pharmaceutical Sciences, University of Manchester and Director of Scientific Development, Simcyp Limited Blades Enterprise Centre, School of Pharmacy and Pharmaceutical Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK.
Mohammad Reza Rouini
Professor of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein Salehi-Surmaghi
Associate Professor of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Satyajit D.Sarker
Department of Pharmacy, School of Applied Sciences, University of Wolverhampton, West Midlands, UK.
Hosnieh Tajerzadeh
Professor of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Emad Tajkhorshid
Associate Professor of Biochemistry, Biophysics and Pharmacology, Departments of Biochemistry and Pharmacology, Beckman Institute, and Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
|
刊名字顺( Alphabetical List of Journals):
返回页首 